Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer

Abstract

Breast cancer is one of the leading causes of death in women in the United States. In general, patients with breast cancer undergo surgical resection of the tumor and/or receive drug treatment to kill or suppress the growth of cancer cells. In this regard, small molecule kinase inhibitors serve as an important class of drugs used in clinical and research settings. However, the development of resistance to these compounds, in particular HER2 and CDK4/6 inhibitors, often limits durable clinical responses to therapy. Emerging evidence indicates that PI3K/AKT/mTOR pathway hyperactivation is one of the most prominent mechanisms of resistance to many small molecule inhibitors as it bypasses upstream growth factor receptor inhibition. Importantly, the PI3K/AKT/mTOR pathway also plays a pertinent role in regulating various aspects of cancer metabolism. Recent studies from our lab and others have demonstrated that altered lipid metabolism mediates the development of acquired drug resistance to HER2-targeted therapies in breast cancer, raising an interesting link between reprogrammed kinase signaling and lipid metabolism. It appears that, upon development of resistance to HER2 inhibitors, breast cancer cells rewire lipid metabolism to somehow circumvent the inhibition of kinase signaling. Here, we review various mechanisms of resistance observed for kinase inhibitors and discuss lipid metabolism as a potential therapeutic target to overcome acquired drug resistance.

Keywords

Drug resistance / lipid metabolism / small molecule inhibitor / tyrosine kinase / HER2

References

[1] Bhullar KS,McGowan EM,Jha A.Kinase-targeted cancer therapies: progress, challenges and future directions..Mol Cancer2018;17:48 PMCID:PMC5817855

[2] Roskoski R Jr.Properties of FDA-approved small molecule protein kinase inhibitors..Pharmacol Res2019;144:19-50

[3] Garrett JT,Rinehart C,Sánchez V.Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase..Pro Natl Acad Sci USA2011;108:5021-6 PMCID:PMC3064360

[4] Canfield K,Wilkins OM,Ung M.Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells..Cell Cycle2015;14:648-55 PMCID:PMC4614407

[5] Polli JW,Harmon KA,O’mara MJ.The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl) oxy] phenyl}-6-[5-({[2-(methylsulfonyl) ethyl] amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions..Drug Metab Dispos2008;36:695-701

[6] Kataoka Y,Shimada H,Hirai M.Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines..Ann Oncol2009;21:255-62

[7] Ferlay J,Soerjomataram I,Parkin DM.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods..Int J Cancer2019;144:1941-53

[8] Brünner-Kubath C,Saferding V,Singer CF.The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells..Breast Cancer Res Treat2011;129:387-400

[9] Joly MM,Jones B,Estrada MV.Rictor/mTORC2 drives progression and therapeutic resistance of HER2-amplified breast cancers..Cancer Res2016;76:4752-64 PMCID:PMC5758362

[10] Eichhorn PJ,Scaltriti M,Guzman M.Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235..Cancer Res2008;68:9221-30 PMCID:PMC2587064

[11] Brady SW,Seok D,Yu D.Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor..Mol Cancer Ther2014;13:60-70 PMCID:PMC3902650

[12] Pavlova NN.The emerging hallmarks of cancer metabolism..Cell Metab2016;23:27-47 PMCID:PMC4715268

[13] Beloribi-Djefaflia S,Guillaumond F.Lipid metabolic reprogramming in cancer cells..Oncogenesis2016;5:e189 PMCID:PMC4728678

[14] Liu Q,Halim A.Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer..Cancer Lett2017;401:39-45

[15] Zaidi N,Kuemmerle NB,Swinnen JV.Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids..Prog Lipid Res2013;52:585-9 PMCID:PMC4002264

[16] Wang T,Lee H,Tripathi SC.JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance..Cell Metab2018;27:136-50 PMCID:PMC5777338

[17] Chen CL,Punj V,Sher L.NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism..Cell Metab2016;23:206-19 PMCID:PMC4715587

[18] Feng WW,Bang S,Li J.CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies..Cell Rep2019;29:3405-20

[19] Wang Q,Spangle JM,Roberts TM.PI3K-p110α mediates resistance to HER2-targeted therapy in HER2⁺, PTEN-deficient breast cancers..Oncogene2016;35:3607 PMCID:PMC4846581

[20] Krycer JR,Luu W.The Akt-SREBP nexus: cell signaling meets lipid metabolism..Trends Endocrinol Metab2010;21:268-76

[21] Wang C,Hu L,Yang P.Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis..Biochem Biophys Res Commun2014;447:57-63

[22] Yue S,Lee SY,Shao T.Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness..Cell Metab2014;19:393-406 PMCID:PMC3969850

[23] Fazolini NP,Werneck MB,Maya-Monteiro CM.Leptin activation of mTOR pathway in intestinal epithelial cell triggers lipid droplet formation, cytokine production and increased cell proliferation..Cell Cycle2015;14:2667-76 PMCID:PMC4614828

[24] Sipula IJ,Perdomo G.Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation..Metabolism2006;55:1637-44

[25] Brown NF,Sipula IJ.The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes..Metabolism2007;56:1500-7

[26] Puig T,Cufí S,Turrado C.A novel inhibitor of fatty acid synthase shows activity against HER2⁺ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines..Breast Cancer Res2011;13:R131 PMCID:PMC3326573

[27] Blancafort A,Oliveras G,Turrado C.Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs..PLoS One2015;10:e0131241 PMCID:PMC4479882

[28] Slamon DJ,Wong SG,Ullrich A.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene..Science1987;235:177-82

[29] Arteaga CL,Osborne CK,Puglisi F.Treatment of HER2-positive breast cancer: current status and future perspectives..Nat Rev Clin Oncol2012;9:16

[30] Tzahar E,Chen X,Karunagaran D.A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor..Mol Cell Biol1996;16:5276-87 PMCID:PMC231527

[31] Xia W,Ho P.Truncated ErbB2 receptor (p95 ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016..Oncogene2004;23:646

[32] Xia W,Liu L,Ory TL.Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells..Oncogene2005;24:6213

[33] O’Donovan N,O’Connor AE,Gallagher WM.Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells..Invest New Drugs2011;29:752-9

[34] Blackwell KL,Tan-Chiu E,Arbushites MC.Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens..Ann Oncol2009;20:1026-31

[35] Geyer CE,Lindquist D,Romieu CG.Lapatinib plus capecitabine for HER2-positive advanced breast cancer..N Engl J Med2006;355:2733-43

[36] Cameron D,Press M,Pienkowski T.A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses..Breast Cancer Res Treat2008;112:533-43

[37] Baselga J,Eidtmann H,De Azambuja E.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial..Lancet2012;379:633-40 PMCID:PMC5705192

[38] Lin NU,Paul D,Christodoulou C.Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer..Clin Cancer Res2009;15:1452-9

[39] Sato Y,Takakura N.Heregulin induces resistance to lapatinib-mediated growth inhibition of HER 2-amplified cancer cells..Cancer Sci2013;104:1618-25

[40] Leung WY,Sheldon H,Li JL.Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer..Oncotarget2015;6:5678 PMCID:PMC4467394

[41] Komurov K,Muller M,Moss TJ.The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells..Mol Syst Biol2012;8:596 PMCID:PMC3421441

[42] Ruprecht B,Zecha J,Berkers CR.Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis..Cancer Res2017;77:1842-53

[43] Deblois G,Tam IS,Caron M.ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer..Nat Commun2016;7:12156 PMCID:PMC4945959

[44] Yang L,Shen E,Li L.NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells..Int J Oncol2017;51:1553-62

[45] Zhao Y,Liu Z,LeDoux SP.Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism..Cancer Res2011;71:4585-97 PMCID:PMC3129363

[46] Burstein HJ,Dirix LY,Paridaens R.Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer..J Clin Oncol2010;28:1301-7

[47] Conlon N,Breen L,O’Driscoll L.64P The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models..Ann Oncol2019;30:mdz238-062

[48] Sudhan DR,Won H,Servetto A.Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers..Cancer Cell.Forthcoming 2019;

[49] Osborne CK,Dirix LY,Robert J.Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study..Clin Cancer Res2011;17:1147-59 PMCID:PMC3074404

[50] Ring A,Hatcher H,Plummer R.Phase I study to assess the combination of afatinib with trastuzumab in patients with advanced or metastatic HER2-positive breast cancer..Clin Cancer Res2015;21:2737-44

[51] Blair HA.Pyrotinib: first global approval..Drugs2018;78:1751-5

[52] Hanahan D.The hallmarks of cancer..Cell2000;100:57-70

[53] Sherr CJ.CDK inhibitors: positive and negative regulators of G1-phase progression..Genes Dev1999;13:1501-12

[54] Dean JL,McClendon AK,Knudsen ES.Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure..Oncogene2010;29:4018

[55] O’Leary B,Turner NC.Treating cancer with selective CDK4/6 inhibitors..Nat Rev Clin Oncol2016;13:417

[56] Portman N,Carson E,Lim E.Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer..Endocr Relat Cancer2019;26:R15-30

[57] Finn RS,Lang I,Bondarenko IM.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study..Lancet Oncol2015;16:25-35

[58] Finn RS,Rugo HS,Im SA.Palbociclib and letrozole in advanced breast cancer..N Engl J Med2016;375:1925-36

[59] Cristofanilli M,Bondarenko I,Im SA.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial..Lancet Oncol2016;17:425-39

[60] Finn RS,Conklin D,Cohen DJ.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro..Breast Cancer Res2009;11:R77 PMCID:PMC2790859

[61] Kenny FS,Musgrove EA,Blamey RW.Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer..Clin Cancer Res1999;5:2069-76

[62] Sabbah M,Mester J.Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element..Proc Natl Acad Sci U S A1999;96:11217-22 PMCID:PMC18014

[63] Musgrove EA,Barraclough J,Sutherland RL.Cyclin D as a therapeutic target in cancer..Nat Rev Cancer2011;11:558

[64] Vora SR,Kim N,Huynh T.CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors..Cancer Cell2014;26:136-49 PMCID:PMC4155598

[65] Herrera-Abreu MT,Asghar U,Cutts RJ.Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer..Cancer Res2016;76:2301-13 PMCID:PMC5426059

[66] Zhang J,Liu P,Wang B.Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt..Molecular Cell2016;62:929-42 PMCID:PMC4912424

[67] Knudsen ES.The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies..Trends Cancer2017;3:39-55 PMCID:PMC5347397

[68] Franco J,Freinkman E,Knudsen ES.Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities..Cell Rep2016;14:979-90 PMCID:PMC4757440

[69] Costa C,Ly A,Ellen M.PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer..Cancer Discov2019;

[70] O’Brien NA,Ayala R,Issakhanian S.In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. AACR Annual Meeting2014;2014 April 5-9San Diego, CA

[71] Michaloglou C,Siersbaek R,Curwen JO.Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer..Mol Cancer Ther2018;17:908-20 PMCID:PMC6485624

[72] Franco J,Knudsen ES.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer..Oncotarget2014;5:6512 PMCID:PMC4171647

[73] Yang C,Bhatt T,Giri D.Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence..Oncogene2017;36:2255 PMCID:PMC5393973

[74] Caldon CE,Kang J,Boersma MN.Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells..Mol Cancer Ther2012;11:1488-99

[75] Fry DW,Keller PR,Meade M.Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts..Mol Cancer Ther2004;3:1427-38

[76] Condorelli R,O’Shaughnessy J,Bailleux C.Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer..Ann Oncol2017;29:640-5

[77] Engelman JA.Targeting PI3K signalling in cancer: opportunities, challenges and limitations..Nat Rev Cancer2009;9:550

[78] Bachman KE,Samuels Y,Ptak J.The PIK3CA gene is mutated with high frequency in human breast cancers..Cancer Biol Ther2004;3:772-5

[79] Lee JW,Kim SY,Park WS.PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas..Oncogene2005;24:1477

[80] Nahta R.Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway..Clin breast cancer2010;10:S72-8

[81] Miller TW,González-Angulo AM,Mills GB.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer..J Clin Invest2010;120:2406-13 PMCID:PMC2898598

[82] Esposito A,Curigliano G.Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: a review..JAMA Oncol2019;

[83] Greenwell IB,Cohen JB.PI3K inhibitors: understanding toxicity mechanisms and management..Oncology (Williston Park)2017;31:821-8

[84] Juric D,Griffith M,Won HH.Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor..Nature2015;518:240 PMCID:PMC4326538

[85] Nakanishi Y,Spoerke JM,Huw LY.Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110β..Cancer Res2016;76:1193-203

[86] Huw LY,Pandita A,Spoerke JM.Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer..Oncogenesis2013;2:e83 PMCID:PMC3940863

[87] Chakrabarty A,Kuba MG,Arteaga CL.Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors..Proc Natl Acad Sci USA2012;109:2718-23 PMCID:PMC3286932

[88] Mossmann D,Hall MN.mTOR signalling and cellular metabolism are mutual determinants in cancer..Nat Rev Cancer2018;18:744-57

[89] Csibi A,Li C,Choo AY.The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4..Cell2013;153:840-54 PMCID:PMC3684628

[90] Furuta E,Zhan R,Watabe M.Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1..Cancer Res2008;68:1003-11

[91] Wieman HL,Rathmell JC.Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking..Mol Biol Cell2007;18:1437-46 PMCID:PMC1838986

[92] Laplante M.An emerging role of mTOR in lipid biosynthesis..Curr Biol2009;19:R1046-52 PMCID:PMC3390254

[93] Tran Q,Park J,Park J.Targeting cancer metabolism-revisiting the Warburg effects..Toxicol Res2016;32:177 PMCID:PMC4946416

[94] Hudson CC,Chiang GG,Loomis DC.Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin..Mol Cell Biol2002;22:7004-14 PMCID:PMC139825

[95] Menendez JA.Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis..Nat Rev Cancer2007;7:763-77

[96] Röhrig F.The multifaceted roles of fatty acid synthesis in cancer..Nature Reviews Cancer2016;16:732

[97] Kuhajda FP.Fatty acid synthase and cancer: new application of an old pathway..Cancer Res2006;66:5977-80

[98] Ookhtens MU,Lyon IR.Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor..Am J Physiol Regul Integr Comp Physiol1984;247:R146-53

[99] Kamphorst JJ,Fan J,Mathew R.Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids..Proc Natl Acad Sci USA2013;110:8882-7 PMCID:PMC3670379

[100] Alo PL,Marci A,Botti C.Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients..Cancer1996;77:474-82

[101] Wang YY,Li JN,Han WF.Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients..Cancer Lett2001;167:99-104

[102] Alo PL,Piro F,Sebastiani V.Immnunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma..Anticancer Res2007;27:2523-7

[103] Cai Y,Zhang L,Yu D.Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer..Med Oncol2015;32:391 PMCID:PMC4247847

[104] Weiss L,Schreiber R,Fuchs E.Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase..Biol Chem Hoppe-Seyler1986;367:905-12

[105] Ventura R,Waszczuk J,Lai J.Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression..EBioMedicine2015;2:808-24 PMCID:PMC4563160

[106] Jin Q,Boulbes D,Wang YN.Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells..Breast Cancer Res2010;12:R96 PMCID:PMC3046439

[107] Kumar-Sinha C,Lippman ME,Chinnaiyan AM.Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis..Cancer Res2007;63:132-9

[108] Alli PM,Jaffee EM,Kuhajda FP.Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice..Oncogene2005;24:39-46

[109] Kridel SJ,Rozenkrantz N.Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity..Cancer Res2004;64:2070-5

[110] Alwarawrah Y,Loiselle D,Darr DB.Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-Neu model of HER2⁺ breast cancer..Cell Chem Biol2016;23:678-88 PMCID:PMC6443244

[111] Zhi J,Funk C,Hopfgartner G.Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers..J Clin Pharmacol1996;36:1006-11

[112] Loftus TM,Frehywot GL,Ronnett GV.Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors..Science2000;288:2379-81

[113] Brenner AJ,Infante JR,Jones SF.First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640..J Clin Oncol2015;33:TPS2615

[114] Yoon S,Park SW,Ko YK.Up-regulation of acetyl-CoA carboxylase α and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells..J Biol Chem2007;282:26122-31

[115] Wang D,Wei J,Jiang G.ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis..Tumor Biol2017;39:1010428317698338

[116] Svensson RU,Eichner LJ,Wallace M.Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models..Nat Med2016;22:1108 PMCID:PMC5053891

[117] Hatzivassiliou G,Bauer DE,Shaw AN.ATP citrate lyase inhibition can suppress tumor cell growth..Cancer Cell2005;8:311-21

[118] Porstmann T,Chung YL,Griffiths JR.PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP..Oncogene2005;24:6465

[119] Porstmann T,Griffiths B,Wu M.SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth..Cell Metab2008;8:224-36 PMCID:PMC2593919

[120] Nieman KM,Penicka CV,Buell-Gutbrod R.Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth..Nat Med2011;17:1498 PMCID:PMC4157349

[121] Balaban S,Lee LS,Schreuder M.Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration..Cancer Metab2017;5:1 PMCID:PMC5237166

[122] Kuemmerle NB,Lombardo PS,Lipe BC.Lipoprotein lipase links dietary fat to solid tumor cell proliferation..Mol Cancer Ther2011;10:427-36 PMCID:PMC3074101

[123] Goldberg IJ,Abumrad NA.Regulation of fatty acid uptake into tissues: lipoprotein lipase-and CD36-mediated pathways..J Lipid Res2009;50:S86-90 PMCID:PMC2674753

[124] Pascual G,Mejetta S,Castellanos A.Targeting metastasis-initiating cells through the fatty acid receptor CD36..Nature2017;541:41

[125] Ladanyi A,Kenny HA,Mitra AK.Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis..Oncogene2018;37:2285 PMCID:PMC5920730

[126] Warburg O.On the origin of cancer cells..Science.1956;123:309-14

[127] Liu Y.Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer..Prostate Cancer Prostatic Dis2006;9:230

[128] Camarda R,Kohnz RA,Mahieu C.Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer..Nat Med2016;22:427 PMCID:PMC4892846

[129] Giudetti AM,Ragusa A,Gaballo A.A specific lipid metabolic profile is associated with the epithelial mesenchymal transition program..Biochim Biophys Acta2019;1864:344-57

[130] McDonnell E,Fox DB,Ilkayeva OR.Lipids reprogram metabolism to become a major carbon source for histone acetylation..Cell Rep2016;17:1463-72 PMCID:PMC5123807

[131] Corbet C,Martherus R,Polet F.Acidosis drives the reprogramming of fatty acid metabolism in cancer cells through changes in mitochondrial and histone acetylation..Cell Metab2016;24:311-23

[132] Balaban S,Varney B,Gao Q.Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate-induced apoptosis..Mol Oncol2018;12:1623-38 PMCID:PMC6120225

[133] Nomura DK,Niessen S,Ng SW.Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis..Cell2010;140:49-61 PMCID:PMC2885975

[134] Jarc E,Malavašič P,Zimmermann R.Lipid droplets induced by secreted phospholipase A2 and unsaturated fatty acids protect breast cancer cells from nutrient and lipotoxic stress..Biochim Biophys Acta2018;1863:247-65

[135] Bi J,Zanca C,Zhang W.Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling..Cell Metab2019;30:525-38 PMCID:PMC6742496

[136] Dubianski R,Leszczynski M,Olszewski W.17P HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch..Ann of Oncol2018;29:

[137] Hultsch S,Paavolainen L,Ikonen E.Association of tamoxifen resistance and lipid reprogramming in breast cancer..BMC Cancer2018;18:850 PMCID:PMC6109356

[138] Du T,Levine KM,Riggins RB.Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer..Breast Cancer Res2018;20:106 PMCID:PMC6124012

[139] Jin J,Nguyen TP,Wright M.Activation of CDK4 triggers development of non-alcoholic fatty liver disease..Cell Rep2016;16:744-56 PMCID:PMC6072278

[140] Kitajima S,Kohno S,Suzuki S.The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity..Oncogene2017;36:5145

[141] Tarrado-Castellarnau M,Tarragó-Celada J,Yuneva M.De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition..Mol Syst Biol2017;13: PMCID:PMC5658703

[142] Alwarawrah Y,Safi R,Spector NL.Overcoming lapatinib resistance by the fatty acid synthase inhibitor HS-106. AACR 106th Annual Meeting2015;2015 April 18-22Philadelphia, PA

[143] Vazquez-Martin A,Brunet J.Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin™) by transcriptionally inhibiting ‘HER2 super-expression’ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells..Int J Oncol2007;31:769-76

[144] Samudio I,Fiegl M,Konopleva M.Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction..J Clin Invest2010;120:142-56 PMCID:PMC2799198

[145] Zaugg K,Reilly PT,Kiarash R.Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress..Genes Dev2011;25:1041-51 PMCID:PMC3093120

[146] Li J,Zhou X,Zhao L.Inhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung adenocarcinoma cell to paclitaxel..PLoS One2013;8:e74623 PMCID:PMC3770579

[147] Wu X,Wang J,Marcus MT.Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer..PLoS One2013;8:e77060 PMCID:PMC3796543

[148] Huang J.A complex interplay between Akt, TSC2 and the two mTOR complexes..Biochem Soc Trans2009;37:217-22 PMCID:PMC2778026

[149] Long X,Ortiz-Vega S,Avruch J.Rheb binds and regulates the mTOR kinase..Curr Biol2005;15:702-13

[150] Nardella C,Salmena L,Alimonti A.Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events..Genes Dev2008;22:2172-7 PMCID:PMC2518820

[151] Vander Haar E,Bandhakavi S,Kim DH.Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40..Nat Cell Biol2007;9:316

[152] Chen Y,He Q,Toral-Barza L.mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer..Oncotarget2016;7:25224 PMCID:PMC5041899

[153] Guri Y,Dazert E,Roszik J.mTORC2 promotes tumorigenesis via lipid synthesis..Cancer Cell2017;32:807-23

[154] Inoki K,Guan KL.TSC2 mediates cellular energy response to control cell growth and survival..Cell2003;115:577-90

[155] Alers S,Wesselborg S.Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks..Mol Cell Biol2012;32:2-11 PMCID:PMC3255710

[156] Hindupur SK,Hall MN.The opposing actions of target of rapamycin and AMP-activated protein kinase in cell growth control..Cold Spring Harb Perspect Biol2015;7:a019141 PMCID:PMC4526743

[157] Hardie DG,Hawley SA.AMPK: a nutrient and energy sensor that maintains energy homeostasis..Nat Rev Mol Cell Biol2012;13:251 PMCID:PMC5726489

[158] Gwinn DM,Egan DF,Mery A.AMPK phosphorylation of raptor mediates a metabolic checkpoint..Mol Cell2008;30:214-26 PMCID:PMC2674027

[159] Hsieh FS,Hung MH,Tsai MH.Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK 4/6-independent manner..Mol Oncol2017;11:1035-49 PMCID:PMC5537702

[160] Lopez-Mejia IC,Giralt A,Zanou N.CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation..Mol Cell2017;68:336-49